Strategic Initiative

Slingshot members are tracking this corporate initiative:

Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Management Comment "We are excited to have reached this agreement with Bristol-Myers Squibb, one of the most innovative biopharmaceutical companies today. This strategic collaboration is by far the largest one we have entered into up to now; it will allow us to fully exploit the potential of our technology platforms in both chemistry and biology. In addition to advancing our internal and already partnered programs, this new collaboration with Bristol-Myers Squibb may generate new treatment options for patients that have no solutions today – and that is what we are here for”, said Philippe Genne, PhD, founder and CEO of Oncodesign. “Nanocyclix® has generated a broad diversity of entirely novel molecules that have unique properties and that seem to match well with programs of interest to Bristol-Myers Squibb”, added Jan Hoflack, PhD, CSO of Oncodesign. “The potential of using our macrocycles in multiple therapeutic areas, both on defined targets and in phenotypic approaches further expands the application of our molecules. We are honored that Bristol-Myers Squibb has selected our technologies to advance on programs that they have highly prioritized”.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jan 05, 2016
Projected Implementation:
Q1, 2016
Relevance Tracked Until:
Q1, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Nanocyclix, Predict, Chi-mice, Pharmimage